A comprehensive systematic review of 64 randomized trials confirms that psychosocial interventions for substance use disorder treatment, particularly cognitive behavioral therapy and contingency management, show consistent clinical effectiveness. This evidence synthesis provides clear guidance for clinicians selecting behavioral interventions in addiction medicine practice.
Selective Personality-Targeted Intervention and the Escalation of Substance Use During Adolescence: A Secondary Analysis of A Cluster-Randomized Clinical Trial.
A cluster-randomized trial found that personality-targeted cannabis prevention programs reduced use escalation by 33% among high-risk adolescents. This cognitive-behavioral approach represents a more precise prevention strategy than universal programs by targeting specific personality risk factors.
The effects of cannabidiol on sleep disturbances within a sample of high trait worriers: A double-blind, randomized placebo controlled trial.
A new double-blind, placebo-controlled trial found that CBD showed no significant benefit over placebo for sleep disturbances in adults with high worry levels. This rigorous study challenges popular assumptions about CBD’s effectiveness for sleep and highlights the importance of evidence-based cannabis medicine. The negative findings provide crucial data for clinicians counseling patients about realistic expectations for CBD sleep products.
Oral Cannabidiol in the Treatment of Myofascial Pain Disorder of the Temporomandibular Region: A Placebo-Controlled Randomized Clinical Trial.
A randomized controlled trial found that oral CBD for TMJ pain treatment effectiveness showed no significant improvement over placebo in patients with temporomandibular myofascial pain disorder. This evidence challenges common assumptions about CBD’s utility for jaw-related pain conditions.
Cannabis-based medicines for chronic neuropathic pain in adults.
The 2025 Cochrane review on cannabis neuropathic pain provides the most rigorous analysis of cannabinoid effectiveness for chronic nerve pain. This systematic review update incorporates recent trial data to inform evidence-based clinical decision-making for neuropathic pain treatment options.
Medical marijuana for management of cancer pain: a narrative review.
A 2025 narrative review examines medical marijuana for cancer pain management across 20 recent studies, highlighting ongoing knowledge gaps despite expanding legal access. While the review consolidates current research trends, specific efficacy conclusions require full study analysis beyond this abstract.
Psychological and Psychosocial Interventions for People With Schizophrenia and Co-Occurring Substance Use Disorders: A Systematic Review and Meta-Analysis.
A new systematic review and meta-analysis examines schizophrenia substance use treatment interventions, focusing on psychological and psychosocial approaches for this challenging dual-diagnosis population. The research addresses a critical evidence gap for patients who comprise over 40% of people with schizophrenia but are often excluded from clinical trials.
Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial.
Australian researchers have published a comprehensive medical cannabis driving safety study protocol designed to assess real-world driving performance in patients using therapeutic THC. This two-phase trial could provide critical evidence to inform driving safety policies for the growing medical cannabis patient population.
Medical Cannabis for the Treatment of Peripheral Neuropathy due to Diabetes: A Systematic Review.
New systematic review evidence shows cannabis for diabetic peripheral neuropathy can provide significant pain relief, with THC-containing products demonstrating the strongest efficacy. This research offers clinicians evidence-based guidance for considering cannabinoid interventions in treatment-resistant diabetic nerve pain cases.
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis.
A landmark systematic review published in The Lancet Psychiatry examined cannabinoids for mental health disorders and substance use disorders across 45 years of research. This comprehensive analysis addresses critical evidence gaps for cannabinoids mental health disorders systematic review that directly impacts clinical practice.